Assignee
OMEROS CORP
US·77 granted patents·133 pending applications·971 citations·filing 1999–2025
Top patents by PatentIndex Score
210 records- 0197US7973068B2Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammationOMEROS CORP·Filed 2002·Granted Jul 5, 2011·71 cites·1 claims
- 0297US7067144B2Compositions and methods for systemic inhibition of cartilage degradationOMEROS CORP·Filed 2003·Granted Jun 27, 2006·100 cites·41 claims
- 0397US6645168B2Arthroscopic irrigation solution and method for inhibition of pain and inflammationOMEROS CORP·Filed 2002·Granted Nov 11, 2003·78 cites·36 claims
- 0497US6420432B2Surgical irrigation solution and method for inhibition of pain and inflammationOMEROS CORP·Filed 2001·Granted Jul 16, 2002·83 cites·31 claims
- 0596US9644035B2Methods for treating conditions associated with MASP-2 dependent complement activationOMEROS CORP·Filed 2013·Granted May 9, 2017·18 cites·15 claims
- 0696US9475885B2Compositions for inhibiting MASP-2 dependent complement activationOMEROS CORP·Filed 2015·Granted Oct 25, 2016·15 cites·31 claims
- 0796US7919094B2Methods for treating conditions associated with MASP-2 dependent complement activationOMEROS CORP·Filed 2006·Granted Apr 5, 2011·86 cites·21 claims
- 0895US12030853B2MASP-2 inhibitors and methods of useOMEROS CORP·Filed 2020·Granted Jul 9, 2024·4 cites·14 claims
- 0995US6492332B1Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammationOMEROS CORP·Filed 2000·Granted Dec 10, 2002·126 cites·26 claims
- 1094US9278101B2Ophthalmologic irrigation solutions and methodOMEROS CORP·Filed 2014·Granted Mar 8, 2016·14 cites·13 claims
- 1193US9855246B2Stable preservative-free mydriatic and anti-inflammatory solutions for injectionOMEROS CORP·Filed 2016·Granted Jan 2, 2018·9 cites·15 claims
- 1293US9486406B2Stable preservative-free mydriatic and anti-inflammatory solutions for injectionOMEROS CORP·Filed 2015·Granted Nov 8, 2016·10 cites·13 claims
- 1393US9066856B2Stable preservative-free mydriatic and anti-inflammatory solutions for injectionOMEROS CORP·Filed 2013·Granted Jun 30, 2015·15 cites·16 claims
- 1493US2026035483A1Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and DisordersOMEROS CORP·Filed 2025·Application pending·0 cites
- 1592US11661418B2MASP-2 inhibitors and methods of useOMEROS CORP·Filed 2020·Granted May 30, 2023·4 cites·21 claims
- 1692US10745274B1Nucleic acids encoding antibodies specifically binding to MASP-3OMEROS CORP·Filed 2020·Granted Aug 18, 2020·2 cites·13 claims
- 1792US9399040B2Ophthalmologic irrigation solutions and methodOMEROS CORP·Filed 2013·Granted Jul 26, 2016·11 cites·3 claims
- 1892US2026049158A1Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and DisordersOMEROS CORP·Filed 2025·Application pending·0 cites
- 1991US8343970B2PDE10 inhibitors and related compositions and methodsOMEROS CORP·Filed 2011·Granted Jan 1, 2013·12 cites·42 claims
- 2091US7786139B2PDE10 inhibitors and related compositions and methodsOMEROS CORP·Filed 2008·Granted Aug 31, 2010·16 cites·13 claims
- 2190US11807641B2MASP-2 inhibitors and methods of useOMEROS CORP·Filed 2020·Granted Nov 7, 2023·2 cites·18 claims
- 2290US9585895B2Ophthalmologic irrigation solutions and methodOMEROS CORP·Filed 2015·Granted Mar 7, 2017·5 cites·11 claims
- 2390US8377930B2PDE10 inhibitors and related compositions and methodsOMEROS CORP·Filed 2009·Granted Feb 19, 2013·11 cites·16 claims
- 2489US12195427B2MASP-2 inhibitors and methods of useOMEROS CORP·Filed 2022·Granted Jan 14, 2025·1 cites·18 claims
- 2589US12091468B2Therapeutic antibodies that bind to the serine protease domain of MASP-2 and uses thereofOMEROS CORP·Filed 2023·Granted Sep 17, 2024·1 cites·18 claims
- 2689US8685975B2PDE10 inhibitors and related compositions and methodsOMEROS CORP·Filed 2012·Granted Apr 1, 2014·8 cites·40 claims
- 2788US11883493B2Antibodies specifically binding to MASP-3 for the treatment of various diseases and disordersOMEROS CORP·Filed 2021·Granted Jan 30, 2024·1 cites·17 claims
- 2888US11207275B2Treatment of addiction and impulse-control disorders using PDE7 inhibitorsOMEROS CORP·Filed 2018·Granted Dec 28, 2021·2 cites·14 claims
- 2988US10870708B2Methods for inhibiting angiogenesis in a subject in need thereofOMEROS CORP·Filed 2017·Granted Dec 22, 2020·3 cites·3 claims
- 3088US9220715B2Treatment of addiction and impulse-control disorders using PDE7 inhibitorsOMEROS CORP·Filed 2013·Granted Dec 29, 2015·5 cites·34 claims
- 3188US2025059299A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2024·Application pending·0 cites
- 3287US11584714B2MASP-2 inhibitors and methods of useOMEROS CORP·Filed 2019·Granted Feb 21, 2023·5 cites·13 claims
- 3387US11027015B2Antibodies specifically binding to MASP-3 for the treatment of various diseases and disordersOMEROS CORP·Filed 2020·Granted Jun 8, 2021·1 cites·19 claims
- 3487US10059776B2Methods for treating conditions associated with MASP-2 dependent complement activationOMEROS CORP·Filed 2017·Granted Aug 28, 2018·2 cites·14 claims
- 3587US2024342278A1Antibodies specifically binding to masp-3 for the treatment of various diseases and disordersOMEROS CORP·Filed 2023·Application pending·0 cites
- 3686US2024228665A1Methods for treating conditions associated with masp-2 dependent complement activationOMEROS CORP·Filed 2023·Application pending·0 cites
- 3786US2026062498A1Methods for treating conditions associated with masp-2 dependent complement activationOMEROS CORP·Filed 2025·Application pending·0 cites
- 3886US2024254257A1Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and DisordersOMEROS CORP·Filed 2023·Application pending·0 cites
- 3985US11981749B2Methods for treating conditions associated with MASP-2 dependent complement activationOMEROS CORP·Filed 2020·Granted May 14, 2024·1 cites·8 claims
- 4085US11525011B2Methods of inhibiting MASP-2-dependent complement activation in a subject suffering from catastrophic antiphospholipid syndromeOMEROS CORP·Filed 2019·Granted Dec 13, 2022·1 cites·12 claims
- 4185US9677070B2Composition and method for diversification of target sequencesOMEROS CORP·Filed 2013·Granted Jun 13, 2017·6 cites·28 claims
- 4285US9434707B2PDE10 inhibitors and related compositions and methodsOMEROS CORP·Filed 2015·Granted Sep 6, 2016·3 cites·1 claims
- 4385US2024076409A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2023·Application pending·0 cites
- 4484US7091181B2Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptorsOMEROS CORP·Filed 2001·Granted Aug 15, 2006·22 cites·16 claims
- 4584US6413961B1Irrigation solution and method for inhibition of pain and inflammationOMEROS CORP·Filed 1999·Granted Jul 2, 2002·51 cites·23 claims
- 4683US12351648B2Methods of inhibiting MASP-2 for the treatment and/or prevention of coronavirus-induced acute respiratory distress syndromeOMEROS CORP·Filed 2021·Granted Jul 8, 2025·1 cites·6 claims
- 4783US11453709B2Chimeric inhibitor molecules of complement activationOMEROS CORP·Filed 2020·Granted Sep 27, 2022·1 cites·10 claims
- 4883US11234965B2Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditionsOMEROS CORP·Filed 2019·Granted Feb 1, 2022·1 cites·6 claims
- 4983US9102643B2PDE10 inhibitors and related compositions and methodsOMEROS CORP·Filed 2014·Granted Aug 11, 2015·3 cites·1 claims
- 5083US6740100B2Tendon repair using adhesiveOMEROS CORP·Filed 2002·Granted May 25, 2004·124 cites·19 claims
Showing the top 50 of 210 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →